Skip to content
TearClear logo — Ensuring efficacy without compromising the safety of the ocu...

TearClear

Ensuring efficacy without compromising the safety of the ocular surface

Founded 2015 United States Boston, United States 7 employees Venture round Total: $51.95M Medical Devices, Pharmaceutical

General Information

Company Name TearClear
Founded Year 2015
Location United States Boston, United States
Founders / Decision Makers
Team member
Employees 7
Industries Medical Devices, Pharmaceutical
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with TearClear. To contact TearClear, visit tearclear.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does TearClear compare?

A PDF of TearClear and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting TearClear soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About TearClear

TearClear is an emerging ophthalmic pharmaceutical company founded in 2015 and headquartered in the United States. The company is focused on disrupting the delivery of current topical medications to the ocular surface, particularly in the treatment of glaucoma. Their lead product candidates aim to enhance patient safety and compliance by capturing preservatives before they reach the ocular surface.

With a slogan of "Ensuring efficacy without compromising the safety of the ocular surface," TearClear is positioned as a pioneer in this first-in-class platform of drugs. The company's innovations have attracted significant attention from investors, with their $11.76M Venture Round investment on 11 July 2023 underlining the confidence in their potential.

Operating within the Medical Devices and Pharmaceutical industries, TearClear's unique approach to drug delivery is not only innovative but also addresses a critical need in ophthalmic care. As the company continues to progress, it has the potential to make a significant impact across multiple programs in development and future indications.

Business keywords: ophthalmic pharmaceuticals, medication delivery, glaucoma treatment, ocular surface safety, preservative capture technology, patient compliance, pharmaceutical innovation, eye care, drug delivery systems, ophthalmology, pharmaceutical startups, preservative-free medications, glaucoma medications, ocular health, safety-enhanced medications

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $11.76M -
11 Jul 2023
Debt Financing $5.90M -
26 Apr 2022
Series B $22.00M 3
Bluestem Capital, Flying L Partners +1
11 Aug 2020
Debt Financing $2.79M -
31 Jan 2020
Series A $5.00M -
12 Apr 2019
Series A $4.50M 2
Bluestem Capital, Visionary Ventures
30 May 2017

TearClear Alternatives & Competitors

View All Alternatives
TearClear vs

Promoting Health by Preventing Error

25 employees
Health Care, Medical Devices
TearClear vs

Pioneering advanced respiratory drug delivery solutions for asthma and chronic obstructive pulmonary...

Series D
Biotechnology, Health Care
TearClear vs
Portal Instruments
Portal Instruments United States

Connected, Reusable Drug Delivery

22 employees
Health Care, Medical Devices

FAQ About TearClear

Ensuring efficacy without compromising the safety of the ocular surface
TearClear was founded in 2015.
TearClear is headquartered in Boston, United States.
TearClear operates in Medical Devices and Pharmaceutical. Its work centres on ophthalmic pharmaceuticals, medication delivery, glaucoma treatment and ocular surface safety.
TearClear has approximately 7 employees.
TearClear has completed 6 funding rounds, raising a total of $51.95M. The latest funding stage is Venture round.
Top alternatives and competitors to TearClear include Manrex Ltd., OMNI, Portal Instruments, Laboratorios Ojer Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TearClear and Manrex Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for TearClear, https://bouncewatch.com/company/tearclear, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout